InnoCare Pharma Limited (HKG: 9969)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
6.12
+0.07 (1.16%)
Dec 31, 2024, 12:08 PM HKT
-11.18%
Market Cap 12.64B
Revenue (ttm) 995.67M
Net Income (ttm) -415.92M
Shares Out 1.76B
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,485,000
Open 6.00
Previous Close 6.05
Day's Range 5.94 - 6.14
52-Week Range 4.03 - 7.92
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 28, 2025

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 1,089
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9969
Full Company Profile

Financial Performance

In 2023, InnoCare Pharma's revenue was 738.54 million, an increase of 18.09% compared to the previous year's 625.40 million. Losses were -631.26 million, -28.80% less than in 2022.

Financial numbers in CNY Financial Statements

News

There is no news available yet.